FindTrial
Sign In

WU-CART-007

BIOLOGICAL3 trials

Sponsors

Wugen, Inc., Washington University School of Medicine, Allotera Therapeutics

Conditions

Acute Myeloid LeukemiaAdult T Cell LeukemiaAdult T Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaExtranodal NK/T-cell LymphomaHepatosplenic T-cell Lymphoma

Phase 1

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
CompletedNCT04984356
Wugen, Inc.Lymphoblastic Lymphoma, T-cell Acute Lymphoblastic Leukemia
Start: 2022-01-14End: 2024-08-08Updated: 2025-09-30
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
SuspendedNCT05377827
Washington University School of MedicineAcute Myeloid Leukemia, Adult T Cell Leukemia, Adult T Cell Lymphoma +12
Start: 2023-10-10End: 2027-06-30Updated: 2026-07-21

Phase 2

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RecruitingNCT06514794
Allotera TherapeuticsLymphoblastic Lymphoma, T-cell Acute Lymphoblastic Leukemia
Start: 2025-01-31End: 2028-12-30Target: 125Updated: 2026-09-03

Related Papers

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update
Blood2025-11-03
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Blood2025-05-308 citations
WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
Blood2024-11-051 citations
Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma
Blood2024-11-051 citations
WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Blood2024-11-05
WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001
Blood2024-11-05
Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)
Blood2023-11-0212 citations
P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)
HemaSphere2023-08-0113 citations